KR20200015477A - 신경 퇴행성 질환을 치료하기 위한 cd14 길항제 항체 - Google Patents

신경 퇴행성 질환을 치료하기 위한 cd14 길항제 항체 Download PDF

Info

Publication number
KR20200015477A
KR20200015477A KR1020197033198A KR20197033198A KR20200015477A KR 20200015477 A KR20200015477 A KR 20200015477A KR 1020197033198 A KR1020197033198 A KR 1020197033198A KR 20197033198 A KR20197033198 A KR 20197033198A KR 20200015477 A KR20200015477 A KR 20200015477A
Authority
KR
South Korea
Prior art keywords
seq
antibody
sequence
cdr1
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197033198A
Other languages
English (en)
Korean (ko)
Inventor
게리 루엘린 레드리치
Original Assignee
임플리싯 바이오사이언스 피티와이 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901462A external-priority patent/AU2017901462A0/en
Application filed by 임플리싯 바이오사이언스 피티와이 엘티디 filed Critical 임플리싯 바이오사이언스 피티와이 엘티디
Publication of KR20200015477A publication Critical patent/KR20200015477A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197033198A 2017-04-21 2018-04-20 신경 퇴행성 질환을 치료하기 위한 cd14 길항제 항체 Ceased KR20200015477A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2017901462A AU2017901462A0 (en) 2017-04-21 Agents for treating or preventing motor neurone disease and uses therefor
AU2017901462 2017-04-21
AU2018900762 2018-03-08
AU2018900762A AU2018900762A0 (en) 2018-03-08 “agents for treating disease and uses therefor”
PCT/AU2018/050357 WO2018191786A1 (en) 2017-04-21 2018-04-20 Cd 14 antagonist antibodies for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
KR20200015477A true KR20200015477A (ko) 2020-02-12

Family

ID=63855469

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197033198A Ceased KR20200015477A (ko) 2017-04-21 2018-04-20 신경 퇴행성 질환을 치료하기 위한 cd14 길항제 항체

Country Status (8)

Country Link
US (2) US20200148780A1 (enExample)
EP (1) EP3612566A4 (enExample)
JP (2) JP2020517740A (enExample)
KR (1) KR20200015477A (enExample)
CN (1) CN110831975A (enExample)
AU (1) AU2018255489B2 (enExample)
IL (2) IL270097B2 (enExample)
WO (1) WO2018191786A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217916A1 (en) * 2018-05-10 2019-11-14 The Methodist Hospital Methods for prognosis and management of disease
PE20210186A1 (es) 2018-07-13 2021-02-02 Alector Llc Anticuerpos anti-sortilina y metodos para su uso
TWI877170B (zh) * 2019-06-11 2025-03-21 美商阿列克特有限責任公司 抗揀選蛋白抗體之使用方法
JP2022541646A (ja) * 2019-07-25 2022-09-26 インプリシット・バイオサイエンス・リミテッド 急性神経炎症傷害を処置するための方法および薬剤
CN115103676A (zh) * 2020-02-13 2022-09-23 普瑞尼亚神经治疗有限公司 使用普利多匹定和另一种激活剂治疗肌萎缩侧索的组合疗法
EP4092051A4 (en) * 2020-06-18 2023-09-06 Shenzhen Mindray Bio-Medical Electronics Co., Ltd SOLUBLE ANTI-SUBTYPE CD14 ANTIBODY, KIT AND CORRESPONDING USE
IL301762A (en) 2020-10-07 2023-05-01 Line 6 Biotechnology Inc Methods and materials for the treatment of eye diseases
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117031014A (zh) * 2023-08-14 2023-11-10 陕西脉元生物科技有限公司 抗matr3自身抗体的试剂在制备检测神经系统自身免疫疾病的产品中的应用及试剂盒
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
CN118290585B (zh) * 2024-06-04 2024-08-30 苏州为度生物技术有限公司天津分公司 一种抗人cd14工程抗体及应用
CN120399098B (zh) * 2025-07-03 2025-09-16 上海玄言生物科技有限公司 抗cd14抗体-il-15超级激动剂融合蛋白及其制法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI920450A7 (fi) * 1989-08-01 1992-01-31 Scripps Clinic And Res Foundation Menetelmiä ja koostumuksia verenmyrkytyksen oireiden estämiseksi
ATE335072T1 (de) * 1993-05-28 2006-08-15 Scripps Research Inst Methoden für inhibition der cd14-abhängigen zellaktivierung
DE69534601T2 (de) * 1994-09-16 2006-08-03 The Scripps Research Institute, La Jolla Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
WO2002042333A1 (en) 2000-11-22 2002-05-30 Mochida Pharmaceutical Co., Ltd. Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
CA2590284A1 (en) 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
US20090181008A1 (en) * 2005-11-10 2009-07-16 Satoris, Inc. Methods of treating alzheimer's disease
KR101256837B1 (ko) * 2009-03-09 2013-04-22 경북대학교 산학협력단 가용성 ｃｄ１４의 파킨슨 병 진단 및 치료용 용도
JP5894939B2 (ja) * 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
WO2018165720A1 (en) * 2017-03-17 2018-09-20 Implicit Bioscience Pty Ltd Agents for treating or preventing viral infections and uses therefor
WO2019217916A1 (en) * 2018-05-10 2019-11-14 The Methodist Hospital Methods for prognosis and management of disease

Also Published As

Publication number Publication date
JP2023090751A (ja) 2023-06-29
CN110831975A (zh) 2020-02-21
IL309046A (en) 2024-02-01
AU2018255489B2 (en) 2024-06-13
US20220010025A1 (en) 2022-01-13
AU2018255489A1 (en) 2019-11-07
EP3612566A1 (en) 2020-02-26
IL270097B1 (en) 2024-01-01
IL309046B2 (en) 2025-03-01
US12297287B2 (en) 2025-05-13
EP3612566A4 (en) 2021-03-03
IL270097A (enExample) 2019-12-31
IL309046B1 (en) 2024-11-01
IL270097B2 (en) 2024-05-01
JP2020517740A (ja) 2020-06-18
WO2018191786A1 (en) 2018-10-25
US20200148780A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
US12297287B2 (en) CD14 antagonist antibodies for treating neurodegenerative diseases
JP7730936B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
US11926671B2 (en) Antibodies and polypeptides directed against CD127
JP2024009818A (ja) 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
KR20230005848A (ko) 항-trem2 항체의 사용 방법
US20250334594A1 (en) Methods for the treatment of amyotrophic lateral sclerosis
CA2596986A1 (en) Use of il-17f in diagnosis and therapy of airway inflammation
KR20230116850A (ko) Trem2　작용제 바이오마커 및 이의 사용 방법
EP3082863B1 (en) Alpha-enolase specific antibodies and method of use in immune diseases
JP2009531295A (ja) 自己免疫疾患又は脱髄疾患を処置するための方法
US20250230228A1 (en) Methods and agents for the treatment of ocular disease
JP2018506275A (ja) 多発性硬化症の遺伝子発現マーカー及び治療
US20250186439A1 (en) Pyk2 inhibition modulates immune cell function
HK40087465A (zh) 抗trem2抗体的使用方法
EA041126B1 (ru) Антитела и полипептиды, направленные против cd127
OA19665A (en) Antibodies and polypeptides directed against CD127.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191108

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210413

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231013

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 20240624

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D